Beacon Therapeutics’ gene therapy shows 12-month benefit
Beacon Therapeutics’ gene therapy has shown a 12-month benefit in a Phase II study in patients with X-linked retinitis pigmentosa…
News
enGene reports interim data from LEGEND trial of detalimogene voraplasmid
Entrada’s stock drops as DMD drug’s efficacy falls short
MEDSIR reports PHERGain and PHERGain-2 trial results for breast cancer
Moderna’s mRNA flu vaccine more effective than current SOC
Taimei Technology and C&R Research to develop AI clinical trial operations platform
Patient enrolment concludes in Alebund’s Phase III trial of AP301
WHO releases online course for clinical trial best practices
